Exchange Capital Management Inc. Acquires 2,418 Shares of Johnson & Johnson (NYSE:JNJ)

Exchange Capital Management Inc. lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 14.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 19,693 shares of the company’s stock after purchasing an additional 2,418 shares during the quarter. Exchange Capital Management Inc.’s holdings in Johnson & Johnson were worth $2,848,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Stack Financial Management Inc grew its position in Johnson & Johnson by 0.5% during the fourth quarter. Stack Financial Management Inc now owns 113,279 shares of the company’s stock worth $16,382,000 after buying an additional 516 shares in the last quarter. Pine Valley Investments Ltd Liability Co lifted its position in shares of Johnson & Johnson by 18.7% during the 4th quarter. Pine Valley Investments Ltd Liability Co now owns 117,542 shares of the company’s stock valued at $16,999,000 after acquiring an additional 18,554 shares during the period. BankPlus Trust Department acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth $392,000. IFP Advisors Inc increased its position in shares of Johnson & Johnson by 6.2% in the fourth quarter. IFP Advisors Inc now owns 32,252 shares of the company’s stock worth $4,665,000 after purchasing an additional 1,873 shares during the period. Finally, RWC Asset Management LLP raised its stake in Johnson & Johnson by 38.1% in the fourth quarter. RWC Asset Management LLP now owns 326,297 shares of the company’s stock valued at $47,189,000 after purchasing an additional 89,969 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Johnson & Johnson

In related news, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mark A. Weinberger purchased 1,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Trading Up 0.4 %

JNJ opened at $163.69 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85. The company’s 50 day moving average price is $150.48 and its two-hundred day moving average price is $156.02. The firm has a market capitalization of $394.11 billion, a price-to-earnings ratio of 24.62, a PEG ratio of 2.56 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Johnson & Johnson’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the prior year, the business posted $2.29 earnings per share. As a group, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.03%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent analyst reports. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Citigroup lowered their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Wolfe Research started coverage on Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price on the stock. Bank of America lowered their price target on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a report on Thursday, January 23rd. Finally, Raymond James reduced their price objective on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $170.67.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.